- RESEARCH HIGHLIGHT
- 23 September 2026
Phase 3 trial data support tambotatug pelitecan as a new second-line treatment for patients with relapsed small-cell lung cancer – a group with few existing treatment options.
Trending
- Grail’s Cancer Blood Test Faces High-Stakes FDA Review
- An antibody–drug conjugate for small-cell lung cancer
- Balancing Quality of Life and Treatment Goals in Relapsed/Refractory Multiple Myeloma
- Background for Subcutaneous Amivantamab Plus Lazertinib in NSCLC
- How Bundled Prophylaxis Changes First-Line Amivantamab Use
- Advocacy and Support in Relapsed/Refractory Multiple Myeloma
- Cornwall bowel cancer campaign aims to boost early diagnosis
- POLE2 of tumor cells promotes OPN secretion based on PCLAF to drive M2 macrophage polarization in clear cell renal cell carcinoma
Wednesday, September 23
